Home > Products > IL17A & IL17F > Recombinant Anti-IL17A x Anti-IL17F Bispecific Antibody (scFv-CH1/CL)

Recombinant Anti-IL17A x Anti-IL17F Bispecific Antibody (scFv-CH1/CL)  (BSCC-176)

Recombinant Anti-IL17A x Anti-IL17F Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-IL17A antibody variable domain is fused to CH1 and the other scFv from an anti-IL17F antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can block two proinflammatory cytokines simultaneously. It is designed for the research of Multiple sclerosis (MS); Autoimmune diseases; Inflammatory diseases therapy.

Specifications

Targets
IL17A & IL17F
Type
scFv-based Bispecific Fragments
Species Reactivity
Human
Target 1
IL17A
Host Animal 1
Mouse
Target 2
IL17F
Host Animal 2
Mouse
Application
FuncS; Promising therapeutic agent
Related Disease
Multiple sclerosis (MS); Autoimmune diseases; Inflammatory diseases

Targets

Target 1
IL17A
Gene ID
UniProt ID
Alternative Names
IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; interleukin-17A; CTLA-8; cytotoxic T-lymphocyte-associated antigen 8; cytotoxic T-lymphocyte-associated protein 8; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)
Target 2
IL17F
Gene ID
UniProt ID
Alternative Names
IL17; Interleukin 17; IL17F; Interleukin 17F; ML1; ML-1; CANDF6; IL-17F; cytokine ML-1

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-IL17A x Anti-IL17F Bispecific Antibody (scFv-CH1/CL) (BSCC-176). Click the button below to contact us or submit your feedback about this product.

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY
Related products of "IL17A & IL17F"
Online Inquiry

24x7 Service quality
USA

Tel:
Fax:
Email:

UK

Tel:
Email:

Germany

Tel:
Email: